News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Karyopharm Therapeutics (KPTI) Announces Award Of Grant From National Multiple Sclerosis Society To Further Develop Selective Inhibitors Of Nuclear Export (SINE) Compounds



1/8/2014 9:29:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NATICK, Mass., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that it has been awarded a grant from the National Multiple Sclerosis (MS) Society through its affiliate, Fast Forward, to support research on the potential of SINE compounds in inflammatory models of disease, including MS. Finding ways to restore and protect the damaged nervous system is a key priority of the National MS Society's No Opportunity Wasted (NOW) research campaign to ultimately eradicate MS.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES